arrow
C

Clémence Henon

institut gustave roussy
H指数:16
被引数:2,311

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Natural history and treatment sensitivity of alveolar soft part sarcoma: A national multicenter analysis from the French sarcoma group

肺泡软组织肉瘤的自然病程和治疗敏感性:法国肉瘤组的全国多中心分析

2026-02-170
OAAI
Multi-omics profiling identified two epithelioid sarcoma molecular subtypes with distinct signaling and immune characteristics

多组学分析鉴定出两种具有不同信号通路和免疫特征的上皮样肉瘤分子亚型

2025-11-280
OAAI
Clinical presentation, management and outcome of 11,132 patients with liposarcoma patients: a population-based study from the NETSARC+ registry

临床表现、治疗管理及结局:11,132例脂肪肉瘤患者的流行病学研究(基于NETSARC+登记系统)

2025-07-310
PREAI
Twenty-year survival of advanced gastrointestinal stromal tumours treated with imatinib: exploratory long-term follow-up of the BFR14 trial

接受伊马替尼治疗的晚期胃肠道间质瘤的二十年生存率:BFR14试验的探索性长期随访

2025-05-280
OAAI
Age Does not Affect the Efficacy of Antibody Drug Conjugates, But is Associated with High-Grade Adverse Events in Patients with Cancer Enrolled in Early Phase Clinical Trials

年龄不影响抗体药物偶联物的疗效,但与在早期临床试验中入组的癌症患者发生高等级不良事件相关。

2025-05-160
PRE
Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial☆

瑞戈非尼作为一线多柔比星类化疗后的维持疗法在进展期非脂肪源性软组织肉瘤患者中的应用:一项双盲随机试验☆

2025-04-080
PRE
A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse

6年与3年伊马替尼辅助治疗局部GIST复发风险高的患者的随机研究

2024-12-016
OAAI
LENVAGIST: A multicentre, comparative, placebo (P)-controlled, double-blinded, phase II study of the efficacy of Lenvatinib (L) in patients with advanced GIST after failure of imatinib and sunitinib

LENVAGIST:一项多中心、比较性、安慰剂(P)对照、双盲、II期研究,旨在评估在伊马替尼和舒尼替尼治疗失败的晚期GIST患者中伦伐替尼(L)的疗效。

2024-09-010
PRE
Prospective validation of the T cell engager (TCE) score in patients treated with bispecific CD3 TCE antibodies in phase I clinical trials

T细胞接合剂(TCE)评分在I期临床试验中使用双特异性CD3 TCE抗体治疗患者的前瞻性验证

2024-09-010
PRE
Single-cell multiomics profiling reveals heterogeneous transcriptional programs and microenvironment in DSRCTs
2024-06-012
OAAI
Improved nationwide survival of sarcoma patients with a network of reference centers
2024-04-019
OA
Subcutaneous fat mass predicts progression-free survival in patients treated with antibody-drug-conjugates in early-phase clinical trials
2024-03-220
PRE
Single-cell multiomics profiling reveals heterogeneous transcriptional programs and microenvironment in desmoplastic small round cell tumors
2024-03-220
PRE
Clinical and translational results of the academic ARIANES Phase 2 basket study: Longitudinal single-cell analysis of patient tumors identifies biological correlates of response to PARP inhibitors and anti-PD-L1 therapy
2024-03-220
PRE
The use of liquid biopsy in patients with advanced pancreatic cancer (PDAC) to guide enrollment in phase I clinical trials
2024-01-160
PRE